Business
Volition Issues Business Review 2025
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.","length":183,"tagName":"p"},{"type":"text","content":"Review of the Year by Cameron Reynolds, Group Chief Executive Officer","length":69,"tagName":"p"},{"type":"text","content":"As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead.","length":146,"tagName":"p"},{"type":"text","content":"Before diving into the detail, I would like to take a moment to reflect on our founding mission. We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal.","length":282,"tagName":"p"},{"type":"text","content":"In this fourth quarter we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France. Our tests are about to be used in both these devastating diseases to help save lives in real world hospital settings: an extremely proud moment for our entire team.","length":515,"tagName":"p"},{"type":"text","content":"Cancer and sepsis are leading causes of death, accounting for approximately a third of deaths worldwide1-3. With the first clinical use now imminent, we are about to be part of the solution, through simple, easy to use, low-cost tests.","length":235,"tagName":"p"},{"type":"text","content":"I believe we will look back on 2025, and indeed in time, the next few quarters, as transformational for the company.","length":116,"tagName":"p"},{"type":"text","content":"2025 efforts for Volition have focused on commercializing our groundbreaking Nu.Q® platform in the human diagnostics market. We were excited to start the implementation of our human licencing strategy; with the signing of not one, but two agreements. The first for Antiphospholipid Syndrome ("APS") with Werfen, and a Co-Marketing and Services Agreement with Hologic. Both are multi-billion-dollar companies, and worldwide ...